NCT01425684

Brief Summary

The principle aim of the project is to identify the key brain circuits associated with smoking and especially smoking in high risk population. The investigators hope that the study will provide concrete biomarkers for new therapeutic development and ultimately reducing the smoking related health burden.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
837

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2010

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 20, 2010

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

August 28, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 30, 2011

Completed
9.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2021

Completed
Last Updated

May 3, 2021

Status Verified

April 1, 2021

Enrollment Period

10.3 years

First QC Date

August 28, 2011

Last Update Submit

April 30, 2021

Conditions

Keywords

MRISmokingSchizophrenia

Outcome Measures

Primary Outcomes (1)

  • Nicotine addiction severity is associated with abnormal functional connectivity as measured by fMRI,compared with nonsmokers.Schizophrenia pts are assoc with add'l functional connectivity impairment compared with controls

    12-15 hours

Secondary Outcomes (1)

  • Symptom and Cognition rating

    1-2 hours

Study Arms (2)

schizophrenia

smokers and nonsmokers

control

smokers and nonsmokers

Eligibility Criteria

Age12 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Smokers, nonsmokers, schizophrenia patients, family members

You may qualify if:

  • Male and Female between ages 12-above (clinical assessments and blood draw only above 62)
  • Ability to give written assent (age below 18)
  • Ability to give written informed consent (age 18 or above)
  • Individuals fulfilled other criteria but over age 62, with major medical illnesses, significant alcohol or other drug use, or unable to undergo MRI may participate in clinical assessments and blood draw if his/her participation forms a family unit (i.e., if at least one of the family member has participated).
  • Subjects above age 62 will not participate in MRI measurements although they may still participate in clinical assessments and blood draw.

You may not qualify if:

  • Inability to sign informed consent/assent
  • For patient participants, Evaluation to Sign Consent (ESC) below 10.
  • Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, stroke, repeated seizure, history of significant head trauma, CNS infection or tumor, other significant brain neurological conditions.
  • Significant alcohol or other drug use (substance dependence within 6 months or substance abuse within 1 month) other than nicotine or marijuana dependence.
  • Woman who are pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self-report; or by positive urine pregnancy test before MRI)
  • Can not refrain from using alcohol and/or marijuana 24 hours or more prior to experiments.
  • For MRI, unable to undergo MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips or other implanted metal parts) or claustrophobic to the scanner

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine

Baltimore, Maryland, 21228, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

* Whole Blood * Saliva

MeSH Terms

Conditions

SchizophreniaPsychotic DisordersSmoking

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental DisordersBehavior

Study Officials

  • L.Elliot Hong, M.D.

    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

August 28, 2011

First Posted

August 30, 2011

Study Start

December 20, 2010

Primary Completion

April 1, 2021

Study Completion

April 1, 2021

Last Updated

May 3, 2021

Record last verified: 2021-04

Data Sharing

IPD Sharing
Will not share

Locations